Market revenue in 2023 | USD 1,077.1 million |
Market revenue in 2030 | USD 1,609.3 million |
Growth rate | 5.9% (CAGR from 2023 to 2030) |
Largest segment | Infectious diseases |
Fastest growing segment | Oncology |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Oncology, Prenatal Testing, Endocrinology, Other Applications, Hematology, Infectious Diseases |
Key market players worldwide | Roche, Abbott Laboratories, Qiagen NV, Bayer AG, Nova Biomedical, Danaher Corp, Nipro Corp, Bio-Rad Laboratories Inc, Agilent Technologies Inc, BioMerieux SA, OraSure Technologies Inc, Abaxis |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to point-of-care molecular diagnostics market will help companies and investors design strategic landscapes.
Infectious diseases was the largest segment with a revenue share of 93.49% in 2023. Horizon Databook has segmented the Asia Pacific point-of-care molecular diagnostics market based on oncology, prenatal testing, endocrinology, other applications, hematology, infectious diseases covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific is expected to be the fastest-growing market over the forecast period. The region is witnessing a significant rise in the adoption of POC molecular diagnostics, driven by the vast and diverse healthcare landscape in the region, encompassing urban centers and remote rural areas, necessitating accessible and rapid diagnostics.
POC molecular tests offer timely results without requiring centralized laboratories, improving healthcare access. Another factor driving the growth is the burden of infectious diseases in the Asia Pacific, including COVID-19, which underscores the urgency for quick and accurate diagnostics. POC molecular tests enable the swift identification of pathogens, aiding containment efforts.
In addition, advancements in miniaturization, automation, and mobile technology are making POC point-of-care molecular diagnostics more feasible and user-friendly. The integration of smartphones or portable devices enhances accessibility, allowing even non-specialist healthcare providers to administer tests.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific point-of-care molecular diagnostics market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific point-of-care molecular diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account